¼Ò¾Æ¾Ï »ýÁ¸ÀÚ¿¡¼­ ´ë»çÁõÈıº ±¸¼º ¿ä¼ÒÀÇ À¯º´·ü
Prevalence of the Components of Metabolic Syndrome in Childhood Cancer Survivors

Clinical Pediatric Hematology-Oncology 2014³â 21±Ç 1È£ p.23 ~ p.28

½ÅÇý°æ(Shin Hye-Kyung) - ÇѾç´ëÇб³ Àǰú´ëÇÐ ¼Ò¾Æ°úÇб³½Ç
ÃÖ¿µÁø(Choi Young-Jin) - ÇѾç´ëÇб³ Àǰú´ëÇÐ ¼Ò¾Æ°úÇб³½Ç
ÀÌ¿µÈ£(Lee Young-Ho) - ÇѾç´ëÇб³ Àǰú´ëÇÐ ¼Ò¾Æ°úÇб³½Ç
½ÅÀçÈÆ(Shin Jeh-Hoon) - ÇѾç´ëÇб³ Àǰú´ëÇÐ ¼Ò¾Æ°úÇб³½Ç
¾ç½Â(Yang Seung) - ÇѸ²´ëÇб³ Àǰú´ëÇÐ ¼Ò¾Æ°úÇб³½Ç

Abstract

Background: Childhood cancer survivors have been reported to have an increased risk of prevalence of metabolic syndrome compared to the normal population. The purpose of this study was to investigate the prevalence of the components of metabolic syndrome in childhood cancer survivors in a single institute.

Methods: The study included survivors who had survived for at least 5 years after off chemotherapy without evidence of recurrence. We measured body mass index (BMI), triglycerides (TG), high-density lipoprotein (HDL)?cholesterol, systolic and diastolic blood pressure, and fasting glucose.

Results: We investigated 58 childhood cancer survivors, median age 5.4 years (range, 0.1?17.2 years) at diagnosis and median follow-up time elapsed after off chemotherapy 7.4 years (range, 4.7?18.6 years). The frequency of metabolic syndrome was 3.4%. The prevalence of each component was: obesity, 17.2%; elevated TG level, 46.6%; low HDL cholesterol, 34.5%; elevated blood pressure, 1.7%; and elevated fasting glucose, 9.3%, respectively. Sixty nine percentage of survivors had at least 1 abnormal component of metabolic syndrome. The increased TG level was found more frequently in obese sub-jects than normal weight subjects.

Conclusion: We observed the high incidence of increased TG level in childhood cancer survivors. It is necessary to be closely monitored the components of metabolic syndrome in childhood cancer survivors, in order to prevent them from cardiovascular diseases and improve their health outcomes.

Ű¿öµå

Childhood cancer survivor, Metabolic syndrome
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø 
ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Ű¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆÇ³âµµ(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
DOI
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå